Nama's AI scorecard currently rates Envista Buy (7.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is NVST's P/E ratio?

Envista trades at a trailing price-to-earnings ratio of 16.2.

When does NVST report earnings?

Envista's next scheduled report is on Feb 3, 2027. Analysts expect EPS of $0.40.

What is the NVST price target?

The median analyst price target from 13 analysts is $28.00, with a range of $23.00 – $34.00.

Is NVST Shariah compliant?

Nama's AAOIFI-style screen reads Envista as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Envista (NVST)

Healthcare · Medical Instruments Supplies · NYSE

Envista (NVST) is a Healthcare company in the Medical Instruments Supplies industry. It has a market capitalization of $4.04B, a trailing price-to-earnings ratio of 16.2 and a free-cash-flow yield of 5.4%. Over the most recent reported fiscal year, revenue grew 8.3% and free cash flow per share fell 22.5%. Nama's AI scorecard rates it Buy, 7.2 out of 10. On 12-month momentum it ranks in the rising band of its market.

AI scorecard

Buy · 7.2/10

Clearly positive, short of the top band. As of Nov 7, 2026.

Momentum

Rising · +18.3% over 12 months ex. last

Second-best fifth of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-51.6%

How far the last close sits under the highest price of the past five years.

Market cap	$4.04B
Trailing P/E	16.2
Price / book	1.3
Price / sales	1.4
FCF yield	5.4%
Dividend yield	—
Gross margin	55.2%
Operating margin	10.4%
Net margin	3.3%
Revenue growth (YoY)	+8.3%
Revenue growth (3-yr annual)	+1.9%
EPS growth (YoY)	+64.4%
FCF/share growth (YoY)	-22.5%
Beta	0.9
Exchange	NYSE
Sector	Healthcare
Industry	Medical Instruments Supplies

NVST earnings

Next report: Feb 3, 2027 (Q4 2026, EPS estimate $0.40). Beat the EPS estimate in 4 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 4, 2026	$0.40	$0.36	+11.1%	$691.50M
Q2 2026	Aug 5, 2026	$0.41	$0.34	+20.6%	$730.50M
Q1 2026	May 6, 2026	$0.36	$0.31	+16.1%	$705.50M
Q4 2025	Feb 5, 2026	$0.38	$0.32	+18.8%	$750.60M

NVST analyst price target

Median target $28.00 from 13 analysts, ranging $23.00 – $34.00.

Medical Instruments Supplies peers

Ticker	Company	Market cap	P/E
ISRG	Intuitive Surgical	$159.96B	41.8
BDX	Becton, Dickinson	$57.71B	16.1
MDLN	Medline	$52.17B	25.1
ALC	Alcon	$36.23B	23.0
RMD	ResMed	$33.10B	20.4
WST	West Pharmaceutical Services	$27.85B	43.5
SOLV	Solventum	$15.38B	12.8
BAX	Baxter International	$13.34B	13.3

Explore live NVST data on Nama Insights →

Recent Congressional trades

Envista trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Pete Sessions	House	Sell	$1,001 - $15,000	Jun 6, 2024

NVST FAQ

Is NVST a buy?: Nama's AI scorecard currently rates Envista Buy (7.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is NVST's P/E ratio?: Envista trades at a trailing price-to-earnings ratio of 16.2.
When does NVST report earnings?: Envista's next scheduled report is on Feb 3, 2027. Analysts expect EPS of $0.40.
What is the NVST price target?: The median analyst price target from 13 analysts is $28.00, with a range of $23.00 – $34.00.
Is NVST Shariah compliant?: Nama's AAOIFI-style screen reads Envista as Not Shariah Compliant. At least one of the three ratios or the industry test failed.